Urology Textbook
Clinical Essentials
By Dirk Manski, MD

 You are here: Urology Textbook > Kidneys > Renal cell carcinoma

Renal Cell Carcinoma: Definition, Epidemiology, and Etiology

Definition of Renal Cell Carcinoma

Renal cell carcinoma (RCC) is the most common malignant tumor of the kidney, accounting for 80–90 % of cases, and arises from the epithelium of the renal tubules (nephron). See the EAU Guidelines and the German S3 Guideline.


Surgical specimen of a clear cell renal cell carcinoma: Typical yellow-brown cut surface and distinct separation from normal kidney tissue. Public domain image of Dr. Edwin P. Ewing, Public Health Image Library, Centers for Disease Control and Prevention, USA, https://phil.cdc.gov.
Surgical specimen of clear cell renal cell carcinoma

Epidemiology of Renal Cell Carcinoma

Cancer statistics:

Mortality:

Mortality has been declining. The approximate age-standardized mortality rate in Germany is 4–5 per 100,000 men and 2 per 100,000 women per year.

Incidence:

The approximate age-standardized incidence rate in Germany is 13–15 per 100,000 men and 6–8 per 100,000 women per year. Incidence increases with age and peaks at 70–75 years. RCC can also occur in children.

Tumor stage:

Most kidney tumors are localized at initial diagnosis. Distant metastases are present at diagnosis in approximately 10 % of patients.

Etiology and Pathogenesis

Tumor Development

Origin:

Clear cell RCC originates in the proximal tubule; other histologic types arise from more distal nephron segments.

Carcinogenic substances:

Smoking (RR 1.4–2.3), trichloroethylene, cadmium, and other solvent or metal exposures are important exogenous risk factors. RCC is rarely recognized as an occupational disease (BK 1302) after substantial exposure to trichloroethylene (TRI).

Epidemiologic risk factors:

Risk factors include end-stage renal disease, acquired cystic kidney disease after long-term dialysis, kidney transplantation, obesity, arterial hypertension, smoking, a positive family history, and hereditary tumor syndromes.

Molecular biology:

Mutations in the VHL gene are detectable in most sporadic RCCs (see below).

Familial Renal Cell Carcinoma

The risk of RCC is approximately doubled in first-degree relatives of affected patients. About 5–8 % of all RCCs occur as part of hereditary syndromes. Findings that suggest hereditary RCC include young age at onset, bilateral or multifocal tumors, a positive family history, and syndrome-specific associated manifestations. The rare genetic syndromes described below are usually inherited in an autosomal dominant manner (Verine et al., 2010).

von Hippel-Lindau disease:

Autosomal dominant inheritance with a high risk of clear cell RCC; see the section on von Hippel-Lindau syndrome for details. The VHL gene is located on chromosome 3p25 and encodes a tumor suppressor protein. Tumors develop according to Knudson's two-hit theory: one affected allele is inherited, and the second alteration results from a somatic mutation or epigenetic inactivation. Tumors develop only when both VHL alleles are inactivated. The probability of developing RCC (penetrance) in patients with von Hippel-Lindau disease is 25–70 %. In these patients, tumors occur earlier, are often multifocal, and may be accompanied by changes in other organs, including the CNS, retina, adrenal glands, and cystic changes in parenchymal organs.

Hereditary papillary renal cell carcinoma (HPRCC):

HPRCC is inherited in an autosomal dominant manner and leads to papillary RCC with basophilic type 1 papillary histology. Mutations in the responsible proto-oncogene MET have been described on chromosome 7. MET encodes the hepatocyte growth factor receptor (HGFR). Other tumor entities, apart from papillary RCC, are not increased in HPRCC. Genetic testing is available.

Tuberous sclerosis:

Tuberous sclerosis increases the risk of renal angiomyolipomas and RCC; see the section on tuberous sclerosis.

Birt-Hogg-Dubé syndrome:

This syndrome is associated with benign skin tumors (fibrofolliculomas), renal tumors (chromophobe RCC, oncocytomas, and, less commonly, clear cell RCC), and pulmonary cysts that may lead to spontaneous pneumothorax. About 25 % of patients develop kidney tumors. The responsible gene, FLCN, encodes folliculin, a protein with tumor suppressor function. The genetic defect is inherited in an autosomal dominant manner, and genetic testing is available (Menko et al., 2009).

Hereditary leiomyomatosis and renal cell cancer syndrome:

This syndrome, associated with cutaneous and uterine leiomyomas, leads to particularly aggressive fumarate hydratase (FH)-deficient RCCs. HLRCC is caused by mutations in the fumarate hydratase gene (FH) and is inherited in an autosomal dominant manner (Badeloe et al., 2009). Genetic testing is available. Unlike in the hereditary syndromes described above, renal tumors in HLRCC should be treated early because they metastasize rapidly.

Tumor Biology

Immunobiology:

RCC induces a marked immune response, which is now used therapeutically mainly through immune checkpoint inhibitors.

Spontaneous regression:

Spontaneous regression of RCC metastases after cytoreductive tumor nephrectomy is rare and is attributed to immunologic factors.

Interferon and interleukin:

Historically, immunotherapy with interferon (IFN) and interleukin (IL) produced response rates of 10–20 %.

Immune checkpoints:

Activation of immune checkpoint receptors suppresses the cellular immune response. Physiologically, these receptors help prevent autoimmune disease. Identified receptors include PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) on T lymphocytes, with corresponding ligands such as PD-L1. Tumors use these pathways to induce immune tolerance. In advanced RCC, inhibition of immune checkpoints with specific antibodies produces significant response rates and improves survival.

Regulation of proliferation and tumor vascularization:

Abundant neovascularization is driven by VEGF overexpression. Increased proliferation is associated with increased expression of TGF-α and EGF receptors, upregulation of Ras-Raf-MAPK signaling, increased expression of the MET proto-oncogene (a receptor tyrosine kinase for hepatocyte growth factor), and activation of mTOR (mechanistic target of rapamycin), a central molecule in intracellular signaling pathways regulating cell growth, angiogenesis, energy balance, and apoptosis. Inhibitors of signal transduction can affect proliferation and vascularization and thereby improve outcomes in patients with metastatic disease.

Regulation of cell adhesion:

Altered intracellular processing of fibronectin, increased expression of proteases such as plasmin and matrix metalloproteinases, and reduced expression of E-cadherin and cadherin-6.

Chemotherapy resistance:

Expression of multidrug resistance protein 1 (MDR1) contributes to the low sensitivity of RCC to cytotoxic chemotherapy. MDR1 (P-glycoprotein) is a transmembrane protein that transports hydrophobic substances out of the cell.




Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

References

Algaba, F.; Akaza, H.; López-Beltrán, A.; Martignoni, G.; Moch, H.; Montironi, R. & Reuter, V. Current pathology keys of renal cell carcinoma.
Eur Urol, 2011, 60, 634-643.

Badeloe, S. & Frank, J. Clinical and molecular genetic aspects of hereditary multiple cutaneous leiomyomatosis.
Eur J Dermatol, 2009, 19, 545-551

DGU; DKG; DKG & Leitlinienprogramm Onkologie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 4.02023 https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom/.

Hock u.a. 2002 HOCK, L. M. ; LYNCH, J. ; BALAJI, K. C.: Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data.
In: J Urol
167 (2002), Nr. 1, S. 57–60

B. Ljungberg et al., “EAU Guidelines: Renal Cell Carcinoma.” (2024). https://uroweb.org/guidelines/renal-cell-carcinoma/

Ljungberg, B.; Campbell, S. C.; Cho, H. Y.; Jacqmin, D.; Lee, J. E.; Weikert, S. & Kiemeney, L. A. The epidemiology of renal cell carcinoma.
Eur Urol, 2011, 60, 615-621.

Menko, F. H.; van Steensel, M. A. M.; Giraud, S.; Friis-Hansen, L.; Richard, S.; Ungari, S.; Nordenskjöld, M.; Hansen, T. V.; Solly, J.; Maher, E. R. & Consortium, E. B. Birt-Hogg-Dubé syndrome: diagnosis and management.
Lancet Oncol, 2009, 10, 1199-1206.

Steffens, S.; Janssen, M.; Roos, F. C.; Becker, F.; Schumacher, S.; Seidel, C.; Wegener, G.; Thüroff, J. W.; Hofmann, R.; Stöckle, M.; Siemer, S.; Schrader, M.; Hartmann, A.; Kuczyk, M. A.; Junker, K. & Schrader, A. J. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - a multicentre study.
Eur J Cancer, 2012, 48, 2347-2352.

Verine, J.; Pluvinage, A.; Bousquet, G.; Lehmann-Che, J.; de Bazelaire, C.; Soufir, N. & Mongiat-Artus, P. Hereditary renal cancer syndromes: an update of a systematic review.
Eur Urol, 2010, 58, 701-710.

WHO Classification of Tumours Editorial Board, Urinary and Male Genital Tumours, 5 ed., vol. 8. in WHO Classification of Tumours, vol. 8. Lyon: International Agency for Research on Cancer, 2022. Accessed: May 11, 2026. [Online]. Available: https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/Urinary-And-Male-Genital-Tumours-2022



  Deutsche Version: Nierenzellkarzinom

Urology-Textbook.com – Choose the Ad-Free, Professional Resource

This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? Join Steady to unlock full access to all images and enjoy an ad-free experience. Try it free for 7 days—no obligation.

New release: The first edition of the Urology Textbook as an e-book—ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.